搜索医生

Roberto A. Leon-Ferre, M.D.

  1. Oncologist
预约门诊

出版物

  1. Jahan N, Taraba J, Boddicker NJ, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, Cathcart-Rake E, O'Sullivan CC, Peethambaram PP, Hobday TJ, Mina LA, Batalini F, Advani P, Sideras K, Haddad TC, Ruddy KJ, Goetz MP, Couch FJ, Yadav S. Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience. Clin Breast Cancer. 2024 Oct 17 [Epub ahead of print]
    View PubMed
  2. Yadav SK, Leon-Ferre RA. Current treatment paradigms for triple-negative breast cancer. Minerva Med. 2024 Oct; 115 (5):589-598 Epub 2024 July 17
    View PubMed
  3. Geurts VCM, Balduzzi S, Steenbruggen TG, Linn SC, Siesling S, Badve SS, DeMichele A, Ignatiadis M, Leon-Ferre RA, Goetz MP, Wolff AC, Klar N, Michiels S, Loi S, Adams S, Horlings HM, Sonke GS, Salgado R, Kok M. Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy. JAMA Oncol. 2024 Aug 1; 10 (8):1077-1086
    View PubMed
  4. Haddad TC, Suman VJ, Giridhar KV, Sideras K, Northfelt DW, Ernst BJ, O'Sullivan CC, Singh RJ, Desta Z, Peethambaram PP, Hobday TJ, Chumsri S, Leon-Ferre RA, Ruddy KJ, Yadav S, Taraba JL, Goodnature B, Goetz MP, Wang L, Ingle JN. Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial. Clin Cancer Res. 2024 Aug 1; 30 (15):3147-3156
    View PubMed
  5. Carroll JF, Hoskin TL, Leon-Ferre RA, Boughey JC. Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Ann Surg Oncol. 2024 Aug; 31(8):5132-5140. Epub 2024 Jun 13.
    View PubMed
  6. Leon-Ferre RA, Whitaker KR, Suman VJ, Hoskin T, Giridhar KV, Moore RM, Al-Jarrad A, McLaughlin SA, Northfelt DW, Hunt KN, Conners AL, Moyer A, Carter JM, Kalari K, Weinshilboum R, Wang L, Ingle JN, Knutson KL, Ansell SM, Boughey JC, Goetz MP, Villasboas JC. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer. Breast Cancer Res. 2024 Jun 10; 26 (1):97 Epub 2024 June 10
    View PubMed
  7. Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clement G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, Andre F, Kok M, Linn SC, Goetz MP, Michiels S, International Immuno-Oncology Biomarker Working Group. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA. 2024 Apr 2; 331 (13):1135-1144
    View PubMed
  8. Leon-Ferre RA, Carter JM, Zahrieh D, Sinnwell JP, Salgado R, Suman VJ, Hillman DW, Boughey JC, Kalari KR, Couch FJ, Ingle JN, Balkenhol M, Ciompi F, van der Laak J, Goetz MP. Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer. NPJ Breast Cancer. 2024 Mar 29; 10 (1):25
    View PubMed
  9. Braune EB, Geist F, Tang X, Kalari K, Boughey J, Wang L, Leon-Ferre RA, D'Assoro AB, Ingle JN, Goetz MP, Kreis J, Wang K, Foukakis T, Seshire A, Wienke D, Lendahl U. Identification of a Notch transcriptomic signature for breast cancer. Breast Cancer Res. 2024 Jan 03; 26(1):4.
    View PubMed
  10. Takchi A, Zhang M, Jalalirad M, Ferre RL, Shrestha R, Haddad T, Sarkaria J, Tuma A, Carter J, David H, Giridhar K, Wang L, Lange C, Lendahl U, Ingle J, Goetz M, D'Assoro AB. Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer. Front Oncol. 2024; 14:1384277 Epub 2024 May 30
    View PubMed
  11. Joshi U, Budhathoki P, Gaire S, Yadav SK, Shah A, Adhikari A, Choong G, Couzi R, Giridhar KV, Leon-Ferre RA, Boughey JC, Hieken TJ, Mutter R, Ruddy KJ, Haddad TC, Goetz MP, Couch FJ, Yadav S. Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2023 Jul; 200 (2):217-224 Epub 2023 May 21
    View PubMed
  12. Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. JAMA Oncology. 2023 Jun 01; 9(6):815-824.
    View PubMed
  13. Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023 May 30; 381:e071674
    View PubMed
  14. Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nat Commun. 2023 Apr 18; 14 (1):2215
    View PubMed
  15. Roesler AS, Malasi S, Koslosky L, Hartmayer P, Naab TJ, Carter JM, Zahrieh D, Hillman D, Leon-Ferre RA, Couch FJ, Goetz MP, Anderson KS, Pockaj BA, Barrett MT. PDJ amplicon in triple negative breast cancer. Sci Rep. 2023 Jan 12; 13 (1):618
    View PubMed
  16. Choong GM, Liddell S, Ferre RAL, O'Sullivan CC, Ruddy KJ, Haddad TC, Hobday TJ, Peethambaram PP, Liu MC, Goetz MP, Giridhar KV. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. Breast Cancer Res Treat. 2022 Nov; 196 (1):229-237 Epub 2022 Aug 31
    View PubMed
  17. O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortes J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep; 195 (2):127-139 Epub 2022 May 11
    View PubMed
  18. Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ. Surveillance mammography after treatment for male breast cancer. Breast Cancer Res Treat. 2022 Aug; 194(3):693-698. Epub 2022 Jun 17.
    View PubMed
  19. D'Assoro AB, D'Assoro AB, Leon-Ferre R, Braune EB, Lendahl U. Roles of Notch Signaling in the Tumor Microenvironment. Int J Mol Sci. 2022 Jun 2; 23 (11) Epub 2022 June 02
    View PubMed
  20. Thompson KJ, Leon-Ferre RA, Sinnwell JP, Zahrieh DM, Suman VJ, Metzger FO, Asad S, Stover DG, Carey L, Sikov WM, Ingle JN, Liu MC, Carter JM, Klee EW, Weinshilboum RM, Boughey JC, Wang L, Couch FJ, Goetz MP, Kalari KR. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 2022 Jun; 4 (2):zcac018 Epub 2022 June 17
    View PubMed
  21. Aspros KGM, Carter JM, Hoskin TL, Suman VJ, Subramaniam M, Emch MJ, Ye Z, Sun Z, Sinnwell JP, Thompson KJ, Tang X, Rodman EPB, Wang X, Nelson AW, Chernukhin I, Hamdan FH, Bruinsma ES, Carroll JS, Fernandez-Zapico ME, Johnsen SA, Kalari KR, Huang H, Leon-Ferre RA, Couch FJ, Ingle JN, Goetz MP, Hawse JR. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFkappaB/p65 signaling in triple negative breast cancer. NPJ Breast Cancer. 2022 Feb 17; 8 (1):20
    View PubMed
  22. Leon-Ferre R, Tan B, Sharma V, Brown M, Cochran J, Desai S, Jahangir A, Hartman J, Yu C, Williams D, Gill A, Liu M, Thompson A, Richardson A, Huang E, Carter JM, Allison KH, Goetz MP, Tung N, Huang R, Tong W, El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1; 7 (1):150 Epub 2021 Dec 01
    View PubMed
  23. Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021 Oct 15; 27(20):5628-5637. Epub 2021 Jun 09.
    View PubMed
  24. Yadav S, Giridhar KV, Leone JP, Leon-Ferre RA, Ruddy KJ. A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer Breast Cancer Management. 2021; 10(3).
  25. Anampa-Guzman A, Loli-Guevara S, Gutierrez-Narvaez CA, Nimboma LE, Leon-Ferre R. ASCO-Sponsored Oncology Student Interest Groups in the World. JCO Glob Oncol. 2021 Sep; 7:1586-1592
    View PubMed
  26. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortes J, O'Shaughnessy J, Dieras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22; 384 (16):1529-1541
    View PubMed
  27. Leon-Ferre RA, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Ann Surg Oncol. 2021 Apr; 28 (4):2111-2119 Epub 2021 Jan 23
    View PubMed
  28. Polley MC, Leon-Ferre RA, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021 Feb; 185(3):557-566. Epub 2021 Jan 03.
    View PubMed
  29. Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Support Care Cancer. 2021 Jan; 29 (1):387-396 Epub 2020 May 06
    View PubMed
  30. Anampa-Guzman A, Brito-Hijar AD, Gutierrez-Narvaez CA, Molina-Ruiz AR, Simo-Mendoza V, Gonzalez-Woge M, de la O Murillo A, Leon-Ferre R. American Society of Clinical Oncology-Sponsored Oncology Student Interest Groups in Latin America. JCO Glob Oncol. 2020 Sep; 6:1439-1445
    View PubMed
  31. Leon-Ferre RA, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A. N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Res Treat. 2020 Aug; 182 (3):613-622 Epub 2020 June 05
    View PubMed
  32. Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M, International Immuno-Oncology Biomarker Working Group. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020 Apr; 250 (5):667-684 Epub 2020 Apr 09
    View PubMed
  33. Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, Dakhil CSR, Rowland KM, Graham ML, Le-Lindqwister N, Smith TJ, Loprinzi CL. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020 Feb; 4 (1):pkz088 Epub 2019 Oct 21
    View PubMed
  34. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb; 18 (2):411-421 Epub 2019 Nov 28
    View PubMed
  35. Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, Leon-Ferre RA, Ruddy KJ. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 2020 Jan 1; 126 (1):26-36 Epub 2019 Oct 07
    View PubMed
  36. Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020; 6:4 Epub 2020 Feb 04
    View PubMed
  37. Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev. 2018 Dec; 37 (4):599-614
    View PubMed
  38. Duma N, Gast KC, Choong GM, Leon-Ferre RA, O'Sullivan CC. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? Curr Oncol Rep. 2018 Jun 8; 20 (8):63 Epub 2018 June 08
    View PubMed
  39. Ravi P, Leon-Ferre R, Thompson CA. 47-Year-Old Woman With Anemia and Thrombocytopenia. Mayo Clin Proc. 2018 Jan; 93 (1):108-112 Epub 2017 Nov 13
    View PubMed
  40. Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018 Jan; 167 (1):89-99 Epub 2017 Sept 14
    View PubMed
  41. McBane Ii R, Loprinzi CL, Ashrani A, Perez-Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. Thromb Haemost. 2017 Oct 05; 117(10):1952-1961. Epub 2017 Aug 24.
    View PubMed
  42. Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, Allred JB, Lowe VJ, Markovic SN. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017 Aug; 27 (4):335-341
    View PubMed
  43. Leon-Ferre R, Ruddy KJ, Staff NP, Loprinzi CL. Fit for Chemo: Nerves May Thank You. J Natl Cancer Inst 2017 Feb; 109 (2) Epub 2016 Oct 28
    View PubMed
  44. Leon-Ferre R, Ruddy KJ, Staff NP, Loprinzi CL. Fit for Chemo: Nerves May Thank You. J Natl Cancer Inst. 2017 Feb; 109(2). Epub 2016 Oct 28.
    View PubMed
  45. Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017 Jan; 52:82-90 Epub 2016 Dec 05
    View PubMed
  46. Leon-Ferre RA, Markovic SN. Nab-paclitaxel in patients with metastatic melanoma. Expert Rev Anticancer Ther. 2015; 15: (12)1371-7.
    View PubMed
  47. Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, Milhem M. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol. 2014 Oct; 74: (4)691-7.
    View PubMed
  48. Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O'Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014 Mar; 43 (2):219-25
    View PubMed
  49. Leon-Ferre R, Koch B, Rosenstein LJ. A B-wildering case of paraplegia: cobalamin deficiency. Am J Med. 2013 Dec; 126: (12)1045-7.
    View PubMed
  50. Leon-Ferre RA, Weiler CR, Halfdanarson TR. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab. Clin Adv Hematol Oncol. 2013 May; 11(5):317-9.
    View PubMed
  51. Leon-Ferre RA, Abu Hejleh TB, Halfdanarson TR. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. Clin Adv Hematol Oncol. 2012 Aug; 10(8):546-8.
    View PubMed
  52. Cherrez Ojeda I, Cruz E, Leon R, Mantilla R, Guerrero T, Soria J, Tafur A, Chica L, Gabino G. Chronic autoimmune urticaria in children. Allergol Immunopathol (Madr). 2009 Jan-Feb; 37: (1)43-7.
    View PubMed
PST-20340745